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INTRODUCTION:  The  peritoneum  is one  of  the  most  common  sites  of  distant  gastrointestinal  stromal  tumor
(GIST)  metastases.  In particular,  GIST  arising  from  the  small  intestine  with  resected  minimal  synchronous
macroscopic  peritoneal  carcinomatosis  or with  primary  tumor  rupture  has  a higher risk  of  developing
peritoneal  recurrence.  Current  clinical  practice  does  not  envisage  second-look  surgery  in  GIST  patients
at  high  risk  of  developing  peritoneal  recurrence,  and  no  literature  data  are  available.
PRESENTATION OF  CASE:  We  describe  a 45-year-old  woman  who  underwent  emergency  surgical  resection
of  jejunal  GIST  presenting  with  spontaneous  tumor  rupture,  synchronous  ovarian  and minimal  macro-
scopic  peritoneal  involvement,  and  subsequent  second-look  surgery  after 13  months  of  imatinib
treatment.
DISCUSSION:  Second-look  surgery  conﬁrmed  a  2.6  cm lesion  close  to the  mesenteric  border  of the  fourth
jejunal  loop,  and  11 peritoneal  lesions  with  a macroscopic  necrotic  aspect  related  to treatment  response.
After  conversion  to  an open  procedure,  a segmental  jejunal  resection  was  performed  with  removal  of all
peritoneal  lesions  and  macroscopic  radical  cytoreduction.
CONCLUSION: Second-look  surgery  in selected  GIST  patients  may  be  performed  after  at least  12  months
of  medical  treatment  with  tyrosine-kinase  inhibitors  to  identify  those  patients  with  limited  peritoneal
disease  not  disclosed  by instrumental  imaging  who  could  undergo  radical  cytoreduction  of  peritoneal
lesions.
ical A© 2012 Surg
. Introduction
Gastrointestinal stromal tumors (GISTs) are common mes-
nchymal tumors in the gastrointestinal tract characterized by
peciﬁc abnormalities of the KIT and PDGFR-alpha (PGDFRA) recep-
ors that are the main oncogenic event and prime therapeutic
argets.1The peritoneum is one of the most frequent sites of dis-
ant recurrences from GISTs.2 In particular, patients with primary
ISTs arising from the small intestine most commonly develop
∗ Corresponding author at: Department of Hematology and Oncology Sciences
L.A.  Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Via Massarenti
,  40138 Bologna, Italy. Tel.: +39 051 6363680; fax: +39 051 6364037.
E-mail  address: maggie.nannini@gmail.com (M.  Nannini).
1 On behalf of Gist Study Group Bologna, Italy.
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abdominal metastases.3 Furthermore, patients with tumor rupture
into the abdominal cavity, both spontaneous or during surgical
procedure, have a higher risk of developing peritoneal recurrence,
especially those undergoing emergency surgery.4 Hence, they are
usually treated as patients with advanced disease.
Current clinical practice does not envisage second-look surgery
in GIST patients at high risk of developing peritoneal recurrence and
these patients are only candidates for treatment with imatinib.
2.  Presentation of case
In March 2010, a 45-year-old woman underwent emergency
surgery for an acute abdomen: a large bleeding ruptured mass
Open access under CC BY-NC-ND license.with cystic features arising from the jejunum and surrounded by
serous-hematic material was found at laparotomy. During abdom-
inal cavity exploration, several vegetating lesions were detected
at the posterior parietal peritoneum and right ovary. Therefore a
 BY-NC-ND license.
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be performed after an adequate medical treatment with tyrosine-ig. 1. The histological examination revealed a complete pathological response,
howing  sclero-hyaline nodules in all samples with no evidence of tumor residues.
ejunal resection was performed with removal of some abdomi-
al nodules. Extemporaneous examination of the ovarian nodule
as negative for tumor localization, so right ovariectomy was not
erformed. Histological examination revealed a 12 cm mixed cell
umor with two mitoses per 50 high-powered ﬁelds (high risk of
ecurrence according to the Miettinen classiﬁcation).5 Immunohis-
ochemistry was positive for CD117, leading to a diagnosis of GIST.
umor genotyping with sequencing for mutations in KIT (exons 9,
1, 13 and 17) and PDGFRa (exon 18) disclosed a deletion c.1665-
679del (p.Gln556 Val560del) at exon 11 of KIT gene. All peritoneal
nd ovarian samples were positive for GIST.
The subsequent CT scan and 18FDG-CT-PET performed two
onths after surgery were negative for synchronous metastases
nd macroscopic peritoneal residue of disease. According to the
isk category and synchronous peritoneal involvement, an adju-
ant treatment with imatinib 400 mg  daily was initiated in May
010 and the following imaging revaluations were negative for
isease relapse. After 13 months of treatment, the patient under-
ent laparoscopic second-look surgery that conﬁrmed the 2.6 cm
esion close to the mesenteric border of the fourth jejunal loop, and
1 peritoneal lesions with a macroscopic necrotic aspect related
o treatment response. After conversion to an open procedure, a
egmental jejunal resection was performed with removal of all
eritoneal lesions and macroscopic radical cytoreduction (R0). His-
ological examination revealed a complete pathological response
howing sclero-hyaline nodules in all samples with no evidence
f tumor residues (Fig. 1) except for the larger jejunal lesion that
urned out to be mesenteric ﬁbromatosis (Fig. 2a and b).
.  Discussion
The peritoneum is one of the most frequent sites of dis-
ant recurrences from GISTs.2 In particular, primary GISTs arising
rom the small intestine most commonly develop abdominal
etastases.3 Furthermore tumor rupture into the abdominal cav-
ty, both spontaneous or during surgical procedure, results in a high
isk for developing peritoneal recurrence, especially in patients
ndergoing emergency surgery.4 However, compared to other can-
ers, second-look surgery in GIST patients at high risk of developing
eritoneal recurrence is not performed in current clinical practice.To our knowledge this is the ﬁrst report on second-look surgery
erformed after 13 months of adjuvant imatinib treatment in a GIST
atient at substantial risk of developing peritoneal recurrence.Fig. 2. (a) Widespread mesenchymal mioﬁbroblastic-like and highly vascularized
cell  proliferation. (b) Strong diffuse -catenin immunoexpression conﬁrming the
diagnosis of mesenteric ﬁbromatosis.
The patient’s high risk of developing peritoneal recurrence was
deﬁned by the following factors: the critical clinical presentation
that required emergency surgery; the spontaneous tumor rupture
discovered during the surgical procedure; multifocal peritoneal
involvement at the time of diagnosis. Even if the post-operative
CT and CT-PET scans performed before starting imatinib and the
subsequent imaging studies during treatment were negative for
macroscopic residual disease, peritoneal involvement was  discov-
ered during second-look surgery. In particular, a 2.6 cm lesion
was found close to the mesenteric border of the fourth jeju-
nal loop and removed performing a segmental jejunal resection.
In addition, 11 millimetric peritoneal lesions were also identi-
ﬁed and removed. The limited peritoneal disease allowed radical
cytoreductive surgery. Macroscopically, all lesions showed clear
necrotic aspects related to imatinib response and the subse-
quent histological examination revealed a complete pathological
response showing sclero-hyaline nodules with no evidence of
tumor residues. In addition, a nodule of mesenteric ﬁbromatosis
was found, supporting the recent already suggested non-random
association between GIST and desmoid tumors.6
This clinical report suggests that second-look surgery in selected
GIST patients at high risk of developing peritoneal recurrence maykinase inhibitors to identify those patients with limited peritoneal
disease not disclosed by instrumental imaging who could undergo
radical removal of peritoneal lesions.
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However, several issues must be addressed. First of all, accu-
ate criteria for the identiﬁcation of high-risk patients are required
o select those who may  really beneﬁt from second-look surgery.
esected minimal synchronous macroscopic peritoneal lesions,
ynchronous ovarian metastases, and perforation of the primary
umor have recently been shown to be accurate criteria for select-
ng asymptomatic patients at high risk of developing colorectal
eritoneal carcinomatosis without any sign of recurrence on imag-
ng studies.7 Small intestine primary GIST, tumor rupture, primary
umor resection in emergency surgery and synchronous periton-
al involvement removed in conjunction with the primary tumor
ay be clinical selection criteria for GIST patients. However, large
rospective clinical trials are needed to conﬁrm these data. It would
lso be interesting to evaluate the role of molecular biology in this
eld, looking for speciﬁc mutations or genomic proﬁle potentially
redictive for peritoneal recurrence.8
Secondly, the best time interval between primary tumor
esection and second-look surgery should be deﬁned. Even if con-
roversial, the maximum time interval between primary colorectal
ancer resection and the planned second-look seems to be one
ear.9 Similarly, second-look surgery in suboptimally debulked
tage III ovarian cancer should be performed within a year.10
he short interval between primary tumor resection and the sub-
equent surgical second-look is due to the natural history of
hese diseases. By contrast, in advanced GIST patients respond-
ng to imatinib, resection of residual disease after at least 12
onths of stable disease, partial response or complete response
hould be considered.11–16 Given this evidence, it is likely that
econd-look surgery for GIST patients at high risk of develop-
ng peritoneal recurrence may  be performed after at least 12
onths of adjuvant medical therapy. In our patient, second-
ook surgery was performed after 13 months of treatment and
he integration between medical and surgical treatment in this
ime interval proved optimal as the complete tumor response
btained by medical treatment allowed radical cytoreductive
urgery.
Thirdly, the management of GIST patients with peritoneal recur-
ence detected during abdominal exploration should be discussed.
ur patient presented focal peritoneal lesions with necrotic aspect
elated to treatment response, allowing radical cytoreduction.
herefore, in case of limited responding peritoneal disease, radical
ytoreduction followed by adjuvant treatment may  be considered,
hereas surgery should be avoided in case of diffuse peritoneal dis-
ase without signs of treatment response, and a change in medical
reatment should be considered.12–14,18
The medical treatment after radical cytoreduction of per-
toneal lesions from GIST remains unsettled, especially for
atients who achieved a complete pathological response. Interna-
ional clinical practice guidelines recommend that patients with
dvanced/recurrent GIST responding to imatinib should continue
reatment indeﬁnitely even in the postoperative setting, and no
ata on discontinuation of therapy in this subset of patients after a
ong treatment period are available.19
A laparoscopic approach should be considered in GIST at least
n the diagnostic phase as it is already performed for second-look
urgery in other malignancies such as ovarian and colorectal cancer,
onverting to open surgery if cytoreduction is needed.
The  role of surgery in GIST management changed after the intro-
uction of imatinib. The efﬁcacy of neo-adjuvant therapy in terms of
ownstaging, allowing surgical removal of non-operable localized
IST at diagnosis and the integration between medical therapies
nd surgery in advanced disease have been already proved. How-
ver, adequate clinical trials have yet to demonstrate the impact
f surgery for residual disease following imatinib treatment on
dvanced GIST patients.11–18 Therefore the appropriate timing of
oth approaches combined is likely to affect the overall survival
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improvement. The possibility of surgical debulking in selected cases
is still a matter of discussion.20
4. Conclusion
In conclusion, second-look surgery in selected GIST patients at
high risk of developing peritoneal recurrence may  be performed
after at least 12 months of medical treatment with tyrosine-kinase
inhibitors to identify those patients with limited peritoneal dis-
ease not disclosed by instrumental imaging who could undergo
radical cytoreduction of peritoneal lesions. Further clinical trials
in large series are needed to conﬁrm these isolated data. Accurate
clinical and biological selection criteria, and proper timing when
planning this procedure and the management of GIST patients
with peritoneal recurrence at abdominal exploration require future
assessment.
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